WO2000037073A1 - Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom - Google Patents
Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom Download PDFInfo
- Publication number
- WO2000037073A1 WO2000037073A1 PCT/DE1999/004071 DE9904071W WO0037073A1 WO 2000037073 A1 WO2000037073 A1 WO 2000037073A1 DE 9904071 W DE9904071 W DE 9904071W WO 0037073 A1 WO0037073 A1 WO 0037073A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cfs
- receptor antagonists
- fatigue
- treatment
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a new use for 5HT 3 receptor antagonists.
- CFS chronic fatigue syndrome
- chronic IV fatigue syndrome was defined as a diagnostic entity in the late 1980s and has been the subject of numerous studies and publications since then.
- CFS chronic mental and physical fatigue
- the object of the present invention is therefore to provide compounds which are suitable for the preparation of medicaments for the treatment of CFS.
- the present invention is based on the finding that the use of antidepressants which enhance the action of serotonin is not appropriate in CFS, as is also supported by the cited study relating to fluoxetine.
- this is a departure from the usual treatment methods, which have essentially focused on the presence of depressive states. It is therefore proposed to use substances that reduce the effect of serotonin, which are channeled through the subset of the so-called 5HT 3 receptors.
- the pharmacologically known class of highly specific 5HT 3 receptor antagonists which are used, for example, in the treatment of emesis in chemotherapy for cancer, is suitable for this purpose.
- the 5HT 3 receptor antagonists used are alosetron, tropisetron, ondansetron, granisetron, bemesetron or combinations of at least two of the above, very selectively active substances. It is preferred that the amount of active ingredient contained in a dose unit is 2 to 10 mg, an amount of active ingredient of 5 to 8 mg in a dose unit being particularly preferred.
- a daily dose generally comprises an amount of active ingredient from 2 to 20 mg, particularly preferably an amount of active ingredient from 5 to 16 mg. If necessary, however, the person skilled in the art is also familiar with varying the amount of active ingredient in a dose unit or the amount of the daily dose according to the requirements.
- the substances used according to the invention for the production of the medicament are preferably oral or intravenous
- Sore throat non-purulent pharyngitis
- the group of patients treated with tropisetron received the active ingredient in the form of a capsule with an active ingredient amount of 5 mg / dose unit, the daily dose also being 5 mg.
- the second group of patients received the active substance ondansetron in tablet form, one dose unit containing 8 mg of active substance and the daily dose consisting of two dose units twice, i.e. 16 mg daily.
- the 5HT 3 receptor antagonists were administered over a period of 15 days. During the study period, patients were tested for the following "listed parameters:
- Analog scales were recorded, which documented the extent of the abnormal fatigue / exhaustion and the reduction in performance.
- the subjectively invented state with regard to fatigue / fatigue or performance was marked on a one-dimensional scale, which covers a range from 0 to 100, where 0 stands for normal fatigue / fatigue or performance and 100 for the greatest fatigue / fatigue or for 100% reduction in performance.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA01006319A MXPA01006319A (es) | 1998-12-22 | 1999-12-22 | Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica. |
CA002356246A CA2356246A1 (en) | 1998-12-22 | 1999-12-22 | Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome |
JP2000589184A JP2002532549A (ja) | 1998-12-22 | 1999-12-22 | 5ht3−受容体−アンタゴニストの使用 |
EP99967889A EP1140076A1 (de) | 1998-12-22 | 1999-12-22 | Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom |
BR9916495-7A BR9916495A (pt) | 1998-12-22 | 1999-12-22 | Uso de 5ht3-receptor-antagonistas |
AU24285/00A AU759250B2 (en) | 1998-12-22 | 1999-12-22 | Use of 5HT3-receptor antagonists for the treatment of chronic fatigue syndrome |
US09/868,972 US6740672B1 (en) | 1998-12-22 | 1999-12-22 | Use of 5HT3-receptor antagonists for the treatment of chronic fatigue syndrome |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19859406.2 | 1998-12-22 | ||
DE19859406 | 1998-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000037073A1 true WO2000037073A1 (de) | 2000-06-29 |
Family
ID=7892223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1999/004071 WO2000037073A1 (de) | 1998-12-22 | 1999-12-22 | Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom |
Country Status (9)
Country | Link |
---|---|
US (2) | US6740672B1 (de) |
EP (1) | EP1140076A1 (de) |
JP (1) | JP2002532549A (de) |
CN (1) | CN1161118C (de) |
AU (1) | AU759250B2 (de) |
BR (1) | BR9916495A (de) |
CA (1) | CA2356246A1 (de) |
MX (1) | MXPA01006319A (de) |
WO (1) | WO2000037073A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014429A1 (ja) * | 2002-08-09 | 2004-02-19 | Mitsubishi Pharma Corporation | 精神疾患発症脆弱性制御剤 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006089100A1 (en) | 2005-02-17 | 2006-08-24 | Amr Technology, Inc. | Benzoxazole carboxamides for treating cinv and ibs-d |
NZ597613A (en) | 2009-07-14 | 2014-01-31 | Albany Molecular Res Inc | 5-ht3 receptor modulators, methods of making, and use thereof |
KR101778439B1 (ko) | 2015-04-27 | 2017-09-14 | 울산대학교 산학협력단 | 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
GB2291591A (en) * | 1994-06-28 | 1996-01-31 | Kenneth Francis Prendergast | Pharmaceutical uses of granisetron |
WO1996012485A1 (en) * | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Treatment of disorders with duloxetine |
US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5712302A (en) * | 1991-06-26 | 1998-01-27 | Sepracor Inc. | Compositions using optically pure R(+) ondansetron |
-
1999
- 1999-12-22 WO PCT/DE1999/004071 patent/WO2000037073A1/de not_active Application Discontinuation
- 1999-12-22 AU AU24285/00A patent/AU759250B2/en not_active Ceased
- 1999-12-22 BR BR9916495-7A patent/BR9916495A/pt not_active IP Right Cessation
- 1999-12-22 US US09/868,972 patent/US6740672B1/en not_active Expired - Fee Related
- 1999-12-22 MX MXPA01006319A patent/MXPA01006319A/es unknown
- 1999-12-22 CN CNB998158445A patent/CN1161118C/zh not_active Expired - Fee Related
- 1999-12-22 EP EP99967889A patent/EP1140076A1/de not_active Withdrawn
- 1999-12-22 CA CA002356246A patent/CA2356246A1/en not_active Abandoned
- 1999-12-22 JP JP2000589184A patent/JP2002532549A/ja not_active Withdrawn
-
2004
- 2004-04-30 US US10/837,370 patent/US20040204467A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
US5712302A (en) * | 1991-06-26 | 1998-01-27 | Sepracor Inc. | Compositions using optically pure R(+) ondansetron |
GB2291591A (en) * | 1994-06-28 | 1996-01-31 | Kenneth Francis Prendergast | Pharmaceutical uses of granisetron |
WO1996012485A1 (en) * | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Treatment of disorders with duloxetine |
US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014429A1 (ja) * | 2002-08-09 | 2004-02-19 | Mitsubishi Pharma Corporation | 精神疾患発症脆弱性制御剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1140076A1 (de) | 2001-10-10 |
JP2002532549A (ja) | 2002-10-02 |
BR9916495A (pt) | 2001-09-04 |
CN1161118C (zh) | 2004-08-11 |
US20040204467A1 (en) | 2004-10-14 |
AU759250B2 (en) | 2003-04-10 |
CA2356246A1 (en) | 2000-06-29 |
AU2428500A (en) | 2000-07-12 |
CN1333684A (zh) | 2002-01-30 |
MXPA01006319A (es) | 2003-06-06 |
US6740672B1 (en) | 2004-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3876877T2 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
DE69929041T2 (de) | Verwendung von cabergolin zur behandlung von "restless legs syndrom" | |
DE69623141T2 (de) | Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen | |
DE68919358T2 (de) | Zusammensetzung zur behandlung der schizophrenie. | |
DE69526918T2 (de) | Arzneimittel gegen spinocerebellare degeneration | |
DE69715899T2 (de) | Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten | |
DE60218193T2 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
EP0065747A1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
DE3883606T2 (de) | Verwendung von Fluoxetin zur Behandlung des Diabetes. | |
DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
WO2000037073A1 (de) | Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom | |
DE10163667B4 (de) | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression | |
DE69331008T2 (de) | Verwendung von cotinin zur linderung des tabakentzugssyndrom | |
DE69708084T2 (de) | Verwendung von pyridyl- und pyrimidyl-piperazinen zur herstellung eines medikaments zur behandlung von rauschgiftsbedingten beschwerden | |
DE60112750T2 (de) | Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen | |
EP0493861B1 (de) | Nicotinamid-adenin-dinukleodid enthaltendes Antidepressionsmittel | |
Haussmann et al. | Das nichtentzugsbedingte Delir. | |
WO2003013521A1 (de) | Verbindungen zur beseitigung und/oder linderung der anhedonie | |
DE69421705T2 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
DE69631597T2 (de) | Kombination aus einem beta rezeptorblocker und einem opioid | |
DE69936773T2 (de) | Behandlung von depression und zusammensetzungen dazu | |
DE60107393T2 (de) | Verwendung von tramadol zur herstellung eines arzneimittels zur behandlung von funktionelle gastrointestinale krankenheiten | |
EP1414424A1 (de) | Mittel zur behandlung der symptome von demenzerkrankungen enthaltend ein zusätzliches lokalanästhetikum | |
CH710163A2 (de) | Bupropion zur Behandlung von Multipler Sklerose. | |
DE3129714A1 (de) | Anti-psychotikum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99815844.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2356246 Country of ref document: CA Ref document number: 2356246 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/006319 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/871/CHE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2000 589184 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999967889 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 24285/00 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868972 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999967889 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 24285/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999967889 Country of ref document: EP |